CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years

India's approval of a recombinant live attenuated dengue vaccine for ages 4 to 60 by the Central Drugs Standard Control Organization (CDSCO) marks a watershed moment in the country's public health journey. Dengue, a mosquito-borne viral disease transmitted primarily by Aedes aegypti, has been endemic in India for decades, with seasonal outbreaks causing significant morbidity and mortality. According to the National Vector Borne Disease Control Programme (NVBDCP), India reports over 100,000 dengue cases annually, with the actual burden estimated to be much higher due to underreporting. The disease imposes a massive economic burden — a 2019 study published in The Lancet estimated India's annual dengue cost at over $1.1 billion, including direct medical expenses and indirect productivity losses. The development of this vaccine represents years of indigenous research, likely involving institutions such as the Indian Council of Medical Research (ICMR), the National Institute of Virology (NIV), Pune, and domestic pharmaceutical companies. The recombinant live attenuated platform is scientifically significant — it uses genetically engineered weakened virus strains to elicit strong, durable immunity without causing disease. This approach mimics natural infection, potentially offering broader protection against all four dengue serotypes (DENV-1 to DENV-4), a critical challenge given that secondary infection with a different serotype increases the risk of severe dengue due to antibody-dependent enhancement (ADE). The CDSCO, functioning under the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019, conducted a rigorous evaluation of quality, safety, and efficacy data — a process aligned with WHO prequalification standards. The Union Health Ministry's announcement underscores the government's commitment to evidence-based regulatory decision-making. This approval also reflects the strengthening of India's regulatory ecosystem, which has gained global recognition, including WHO's maturity level 3 classification for CDSCO in 2022. Constitutionally, public health falls under the State List (Entry 6, List II, Seventh Schedule), but the Centre plays a pivotal role through the Concurrent List (Entry 20A — population control and family planning; Entry 23 — social security and social insurance) and its responsibility for international health regulations under Article 253. The National Health Mission (NHM), Ayushman Bharat, and the Integrated Disease Surveillance Programme (IDSP) provide the implementation framework for vaccine rollout. The broad age indication (4–60 years) is strategically vital — it covers school-going children, working-age adults, and high-risk groups, enabling integration into school health programs, occupational health schemes, and routine immunization under Mission Indradhanush. Economically, this vaccine can reduce out-of-pocket expenditure for millions, especially in urban and peri-urban areas where dengue thrives. It also boosts India's vaccine diplomacy — as the 'pharmacy of the world', India can supply this affordable vaccine to other dengue-endemic nations in South Asia, Africa, and Latin America, enhancing soft power. The approval aligns with the WHO's Global Dengue Control Strategy (2012–2020) and the Sustainable Development Goal 3.3 (ending epidemics of neglected tropical diseases by 2030). Looking ahead, key challenges include ensuring equitable access, cold chain logistics for live vaccines, post-marketing surveillance for rare adverse events (like vaccine-associated enhanced disease), and community acceptance. The government must also address vector control integration — vaccines alone cannot eliminate dengue without sustained source reduction, community engagement, and urban planning reforms. Future steps may include WHO prequalification, inclusion in the Universal Immunization Programme (UIP), and phase IV effectiveness studies. This milestone exemplifies how indigenous innovation, robust regulation, and public health vision can converge to tackle a persistent national challenge.